论文部分内容阅读
从事分子整形术领域研究长达12年的德国Orthogen AG生物技术公司在成功完成临床研究后,计划在全欧洲开展新的关节炎治疗方法Orthokine的销售工作；Orthokine是一种具有抗炎症细胞因子拮抗剂和增长因子的以产生自体条件血清的医疗设备。由两所大学开展的随机双盲研究已证实Orthokine对膝关节炎和腰痛治疗的高效性与安全性。Orthogen公司首席执行官Peter Wehling博士对此强调指出,因临床相关的不良反应报道较少,Orthokine可有效替代类固
Orthogen AG, a German biotech company that has been in molecular plastic surgery for more than 12 years, plans to launch a new sales arm for Orthokine, an arthritis treatment in Europe. Orthokine is an anti-inflammatory cytokine antagonist Agents and growth factors to produce auto-conditioned serum in medical devices. Randomized, double-blind studies conducted by two universities have demonstrated the efficacy and safety of Orthokine in the treatment of knee and back pain. Dr. Peter Wehling, Orthogen CEO, emphasized in this regard that Orthokine is an effective alternative to steroid-induced solid tumors because of fewer reports of clinically relevant adverse events